Objective To evaluate the overexpression of cyclin G1 in cervical intraepithelial neoplasia (CIN) and cervical carcinoma, and the correlation between cyclin G1 and high-risk human papilloma virus (HPV) infection. Meth...Objective To evaluate the overexpression of cyclin G1 in cervical intraepithelial neoplasia (CIN) and cervical carcinoma, and the correlation between cyclin G1 and high-risk human papilloma virus (HPV) infection. Methods All of the specimens were obtained from the Department of Pathology of China-Japan Friendship Hospital from January 2000 to August 2004.We detected the expression of cyclin G1 with immunohistochemistry, HPV16/18 infection with in situ hybridization, and high-risk HPV infection with Hybrid capture system II (HC-II) in normal group (25 cases), CIN I (48 cases), CIN II (56 cases), CIN III (54 cases), and invasive cervical squamous-cell carcinoma (SCC, 31 cases). Results The positive rates of cyclin G1 expression in CIN(77.85%)and SCC cervical tissues (87.10%) were significantly higher than normal (8.00%, P<0.01), and the intensities of cyclin G1 expression in CIN(40.60%)and SCC cervical tissues (61.51%) were significantly higher than normal (2.72%, P<0.05). The positive rates and intensities of cyclin G1 expression increased gradually with the grade of cervical lesions. High-risk HPV infection rates were higher in CIN and SCC than normal groups (P<0.05). There was a positive correlation between cyclin G1 expression and high-risk HPV infection detected with HC-II (Kendall’s tau-b=0.316, 0.269, 0.352, and 0.474 in CIN I, CINII, CIN III, and SCC, respectively, P<0.05). Conclusions Cyclin G1 is overexpressed in CIN and SCC. Cyclin G1 may be a biomarker for detecting CIN and SCC. Cyclin G1 may play an important role in the oncogenesis of CIN and SCC by high-risk HPV infection.展开更多
人乳头状瘤病毒(human papillomavirus,HPV)持续感染是宫颈癌发生发展的促进因素,其致瘤作用主要与其基因表达与蛋白转化有关。目前临床上用于检测HPV的方法主要有免疫组化、原位杂交、核酸印迹、聚合酶链反应(PCR)、第2代杂交捕获法(th...人乳头状瘤病毒(human papillomavirus,HPV)持续感染是宫颈癌发生发展的促进因素,其致瘤作用主要与其基因表达与蛋白转化有关。目前临床上用于检测HPV的方法主要有免疫组化、原位杂交、核酸印迹、聚合酶链反应(PCR)、第2代杂交捕获法(the second generation of hybrid capture,HCⅡ)等,其中HCⅡ是第1个经美国食品和药品管理局(US Food and Drug Administration,FDA)批准的临床检测高危型HPV方法。高危型HPV检测联合细胞学筛查可最大程度优化防癌筛查的流程和宫颈异常细胞的临床处理,同时HPV检测也是宫颈癌治疗后随诊的重要方法。因此HPV检测在宫颈癌筛查、诊断及治疗随访中均具有十分重要的意义。展开更多
文摘Objective To evaluate the overexpression of cyclin G1 in cervical intraepithelial neoplasia (CIN) and cervical carcinoma, and the correlation between cyclin G1 and high-risk human papilloma virus (HPV) infection. Methods All of the specimens were obtained from the Department of Pathology of China-Japan Friendship Hospital from January 2000 to August 2004.We detected the expression of cyclin G1 with immunohistochemistry, HPV16/18 infection with in situ hybridization, and high-risk HPV infection with Hybrid capture system II (HC-II) in normal group (25 cases), CIN I (48 cases), CIN II (56 cases), CIN III (54 cases), and invasive cervical squamous-cell carcinoma (SCC, 31 cases). Results The positive rates of cyclin G1 expression in CIN(77.85%)and SCC cervical tissues (87.10%) were significantly higher than normal (8.00%, P<0.01), and the intensities of cyclin G1 expression in CIN(40.60%)and SCC cervical tissues (61.51%) were significantly higher than normal (2.72%, P<0.05). The positive rates and intensities of cyclin G1 expression increased gradually with the grade of cervical lesions. High-risk HPV infection rates were higher in CIN and SCC than normal groups (P<0.05). There was a positive correlation between cyclin G1 expression and high-risk HPV infection detected with HC-II (Kendall’s tau-b=0.316, 0.269, 0.352, and 0.474 in CIN I, CINII, CIN III, and SCC, respectively, P<0.05). Conclusions Cyclin G1 is overexpressed in CIN and SCC. Cyclin G1 may be a biomarker for detecting CIN and SCC. Cyclin G1 may play an important role in the oncogenesis of CIN and SCC by high-risk HPV infection.
文摘人乳头状瘤病毒(human papillomavirus,HPV)持续感染是宫颈癌发生发展的促进因素,其致瘤作用主要与其基因表达与蛋白转化有关。目前临床上用于检测HPV的方法主要有免疫组化、原位杂交、核酸印迹、聚合酶链反应(PCR)、第2代杂交捕获法(the second generation of hybrid capture,HCⅡ)等,其中HCⅡ是第1个经美国食品和药品管理局(US Food and Drug Administration,FDA)批准的临床检测高危型HPV方法。高危型HPV检测联合细胞学筛查可最大程度优化防癌筛查的流程和宫颈异常细胞的临床处理,同时HPV检测也是宫颈癌治疗后随诊的重要方法。因此HPV检测在宫颈癌筛查、诊断及治疗随访中均具有十分重要的意义。
